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Objective: Features of the metabolic syndrome such as central obesity with insulin resistance and
dyslipidemia are typical signs of Cushing’s syndrome and common side effects of prolonged glu-
cocorticoid treatment.AMP-activatedprotein kinase (AMPK), a key regulatory enzymeof lipid and
carbohydrate metabolism as well as appetite, is involved in the development of the deleterious
metabolic effects of excess glucocorticoids, but no data are available in humans. In the current
study, we demonstrate the effect of high glucocorticoid levels onAMPK activity of human adipose
tissue samples from patients with Cushing’s syndrome.
Methods:AMPKactivity andmRNAexpressionof genes involved in lipidmetabolismwere assessed
in visceral adipose tissue removed at abdominal surgery of 11 patients with Cushing’s syndrome,
nine sex-, age-, andweight-matched patients with adrenal incidentalomas, and in visceral adipose
tissue from four patients with non-endocrine-related abdominal surgery.
Results: The patients with Cushing’s syndrome exhibited a 70% lower AMPK activity in visceral
adipose tissueas comparedwithboth incidentalomasandcontrolpatients (P0.007andP0.001,
respectively). Downstream targets of AMPK fatty acid synthase and phosphoenol-pyruvate car-
boxykinase were up-regulated in patients with Cushing’s syndrome. AMPK activity was inversely
correlated with 0900 h serum cortisol and with urinary free cortisol.
Conclusions: Our data suggest that glucocorticoids inhibit AMPK activity in adipose tissue, sug-
gesting a novelmechanism to explain the deposition of visceral adipose tissue and the consequent
central obesity observed in patients with iatrogenic or endogenous Cushing’s syndrome. (J Clin
Endocrinol Metab 93: 4969–4973, 2008)
Endogenous Cushing’s syndrome is caused by either anACTH-secreting pituitary adenoma, i.e.Cushing’s disease,
or cortisol-secreting adrenal tumors or, more rarely, by ectopic
ACTH-secreting tumors. Whereas endogenous Cushing’s syn-
drome is a relatively rare disease with an estimated incidence
of five to six cases per 106 population per year (1), more than
half a million people in the United Kingdom and some 2.5
million people in the United States are currently exposed to
long-term glucocorticoid treatments (2–4), resulting in exog-
enous Cushing’s syndrome. Complications such as central
obesity, impaired glucose tolerance, dyslipidemia, fatty liver,
hypertension, gastritis, osteoporosis and mood alterations
contribute to the increased cardiovascular risk and the re-
duced quality of life, as well as life expectancy, in these pa-
tients (5). Central obesity, a typical feature of Cushing’s syn-
drome (6), is characterized by the accumulation of abdominal
visceral fat and plays a particularly major role in the devel-
opment of the metabolic complications.
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AMP-activated protein kinase (AMPK) is a sensor of cellular
energy status (7). AMPK is activated by decreases in the energy
state of a cell, and once activated, AMPK switches off anabolic
pathways such as fatty acid synthesis as well as protein synthesis
and switches on catabolic pathways including glycolysis and
fatty acid oxidation.
Manyof the changes seen in glucocorticoid excess correspond
to metabolic steps regulated by AMPK. In an animal model of
Cushing’s syndrome,wehave recently shown that corticosterone
treatment changesAMPKactivity in a tissue-specificmanner (8):
in particular, it causes inhibition of adipose tissue AMPK,which
may explain the accumulation of lipids in visceral fat tissue and,
together with the abnormal liver AMPK activity, contributes to
the development of a fatty liver, dyslipidemia, and insulin resis-
tance. We also observed an increase in hypothalamic AMPK
activity in rats in response to glucocorticoid treatment (8),which
leads to increased hunger, a known symptom of glucocorticoid
excess, even though it is not entirely clear whether this is a direct
effect of glucocorticoids or it is due to insulin resistance (9). Data
supporting a role for AMPK in the metabolic syndrome have
beenobtainedmainly fromstudies in rodents,whereas data from
humans are limited to studies in skeletal muscle of obese or di-
abetic patients (10–12). We have now investigated AMPK ac-
tivity in visceral adipose tissue of patients with Cushing’s
syndrome.
Patients and Methods
Perirenal visceral adipose tissue was sampled during adrenal operations
in 11 patients with Cushing’s syndrome (eight patients with cortisol-
secreting adenomas, two patients with cortisol-secreting adrenal carci-
nomas, and one patient with anACTH-secreting pituitary adenoma (op-
erated for bilateral adrenalectomy because the hypercortisolismwas not
controlled with the other therapeutic approaches) and nine age-, sex-,
and weight-matched control patients with adrenal adenomas that were
not associated with symptoms of excess hormone release and were di-
agnosed as an incidental finding: adrenal incidentalomas. The clinical
diagnosis of Cushing’s syndrome and the nonhypersecreting adrenal ad-
enomas was made on the basis of the clinical presentation, laboratory
testing, and imaging according to published guidelines (5) and was con-
firmed histologically in all patients. Clinical details of the Cushing’s
syndrome and the adrenal incidentaloma patients are given in Table 1.
An additional control group of visceral adipose tissue from four patients
with non-endocrine-related perirenal operations was also analyzed.
Thesepatients hadnoknownendocrinedisorderbut formal testingof the
hypothalamus-pituitary-adrenal axis was not performed.
The study was approved by the local Ethics Committee and all pa-
tients gave written informed consent to participate in the study. Serum
cortisol and ACTH levels were measured by chemiluminescence assays
(Diagnostic Products Corp., Los Angeles, CA). Urinary free cortisol was
measured byRIA (Cortisol Bridge,Athens,Greece) andHPLCaccording
to the modified Santos-Montes method.
AMPK activity assay
The kinase assay for AMPK activity has been previously described
(13, 14). Briefly, samples of adipose tissue were weighed and homoge-
nized with a Precellys 24 machine using CK14 tubes containing ceramic
beads (Stretton Scientific, Stretton, UK) at 6000 rpm for one to three
cycles of 20 sec in lysis buffer containing phosphatase inhibitors, and the
tissue protein content was determined using BCA assay (Pierce, Rock-
ford, IL). AMPK was immunoprecipitated with an equal mixture of
1AMPK and 2AMPK antibodies (13, 14), and AMPK activity was
determined by the entity of 32P incorporation into the AMPK substrate
SAMS (amino acid sequence: HMRSAMSGLHLVKRR; synthesized by
Pepceuticals Ltd., Nottingham, UK). Samples were assayed in duplicate,
and each sample was also assayed without the addition of the substrate
SAMS as a negative control.
Real-time-PCR
Real-time-PCR using predesigned primers (Applied Biosystems Inc.,
Warrington, UK) for fatty acid synthase (FAS) and phosphoenol-pyru-
vate carboxykinase (PEPCK) was performed in human adipose samples
following the protocol we previously described (8). The relative quan-
tities of target transcripts were calculated using the standard curve
method from the data of triplicate samples after normalization against
the housekeeping gene -actin.
Statistical analysis
Student’s t testwasapplied fornormallydistributeddata,whereas the
Mann-Whitney U test or the Kruskal-Wallis test followed by the
Conover-Inman comparisonwas used for nonnormally distributed data.
Correlations were carried out using Spearman’s rank correlations. Data
are shownasmean SEMunless statedotherwise. Symbolsused in figures
are as follows: *, P 0.05, **, P 0.01 and ***, P 0.001, compared
with the relevant control.
TABLE 1. Clinical characteristics of the patients
Cushing’s syndrome (n  11) Adrenal incidentalomas (n  9) P value
Age (yr) 50  11 53  8 NS
Sex (M/F) 2/9 5/4 NS
BMI (kg/m2) 32  7 30  3 NS
WHR 1.01  0.1 0.95  0.1 NS
Adrenal mass size (cm) 4.9  1.8 4.02  0.8
0900 h cortisol (g/dl) nmol/liter 26.8  7.8 742  216 13.8  4.5 381  124 0.001
Urinary free cortisol (g per 24 h)
nmol per 24 h
447  564 1233  1553 98.1  27.8 270  76 0.0001
Cortisol after Dexa 1 mg (g/dl) nmol/liter 20.5  13.8 567  383 2  0.9 55.5  25 0.001
ACTH (pg/ml) pmol/liter 6  2.2 1.3  0.5a 27.6  11.5 6.1  2.5 0.002
All data are shown as mean  SD. Normal range for 0900 h serum cortisol is 5–23 g/dl (138–635 nmol/liter), urinary free cortisol, 13–160 g per 24 h (35.9–441.4
nmol per 24 h), cortisol after overnight dexamethasone test, 1.8 g/dl (50 nmol/liter), and ACTH, 7–65 pg/ml (1.54–14.3 pmol/liter). NS, Not significant; WHR, waist to
hip ratio; Dexa 1 mg, overnight dexamethasone test with 1 mg oral dexamethasone; BMI, body mass index.
a The single patient with pituitary-dependent Cushing’s disease with circulating ACTH of 39 pg/ml (8.6 pmol/liter) was not included in the ACTH calculation in the table
above.
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Results
Hormone and biochemical measurements in patients
with Cushing’s syndrome and nonhypersecreting
adrenal adenomas (adrenal incidentalomas)
The clinical details of patients with Cushing’s syndrome are
shown in Table 1. There was a significant difference between
patientswithCushing’s syndromeandadrenal incidentalomas in
the hormonal parameters of cortisol excess: urinary free cortisol
(P 0.0001), 0900 h serum cortisol (P 0.001), 0900 h serum
cortisol levels after 1 mg dexamethasone at midnight (P 
0.001), and plasma ACTH (P  0.002) the single patient with
pituitary-dependentCushing’s diseasewith circulatingACTHof
39 pg/ml (8.6 pmol/liter) was not included in the ACTH com-
parison (Table 1). Some of the patients with adrenal incidenta-
lomas, in accordance with recent clinical data (15–17), had a
slight increase in their cortisol burden (subclinicalCushing’s syn-
drome), as demonstrated by the fact that five of nine patients
failed to fully suppress their 0900h serumcortisol to less than1.8
g/dl (50nmol/liter).Cortisol levels after dexamethasone1mg
overnight in these five patients were greater than 1.8 g/dl but
less than 5g/dl, suggesting that in these patients themore strin-
gent criterion for nonsuppression was not present. The two
groups were not significantly different in terms of age, sex, or
body mass index.
AMPK activity in visceral adipose tissue
Weobserved amore than 70%reduction inAMPKactivity in
the tissue samples from patients with Cushing’s syndrome com-
paredwithboth control groups:AMPKactivitywas significantly
decreased in the visceral adipose tissue samples from patients
with Cushing’s syndrome compared with patients with adrenal
incidentalomas (0.08  0.03 vs. 0.3  0.07 nmol/minmg, P 
0.007, Fig. 1A). Because patients with incidentalomas have been
shown to occasionally present with signs of mild hypercorti-
solism (15), we also evaluated AMPK activity in the perirenal
adipose tissue from patients with perirenal operations without
underlying endocrine disease. The AMPK activity in patients
with Cushing’s syndrome was again significantly lower com-
paredwith these control patients (AMPKactivity 0.080.03 vs.
0.56 0.1 nmol/minmg, P 0.001, Fig. 1A). The comparison
between AMPK activity of adipose tissue from incidentaloma
patients and nonendocrine disease patients showed a nonsignif-
icant trend (P  0.11) for lower levels in the incidentaloma pa-
tients (Fig. 1A).
In patients with Cushing’s syndrome and adrenal incidentalo-
mas, AMPK activity correlated negatively withmarkers of cortisol
burden: urinary free cortisol (r0.53,P0.02, Fig. 1B), 0900h
serum cortisol (r  0.51, P  0.03, Fig. 1C), and cortisol levels
after 1 mg dexamethasone test (r0.45, P 0.047).
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FIG. 1. A, AMPK activity in visceral adipose tissue of patient with Cushing’s syndrome compared with patients with nonhypersecreting adrenal adenomas
(incidentalomas) and controls. B, Correlation of AMPK activity to urinary free cortisol (UFC) in patients with Cushing’s syndrome and adrenal incidentaloma. The patient
with exceptionally high UFC of 2215 g per 24 h was not included in this figure to allow better representation of the data. C, Correlation of AMPK activity to 0900 h
serum cortisol in patients with Cushing’s syndrome and adrenal incidentaloma. D, FAS mRNA expression in visceral adipose tissue of patients with Cushing’s syndrome
compared with patients with nonhypersecreting adrenal adenomas (incidentalomas) and controls. Data are shown as mean  SEM, n  4–13 patients/group. *, P 
0.05; **, P  0.01; ***, P  0.001.
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RT-PCR
FAS and PEPCK are important rate-limiting enzymes in fatty
acid synthesis and glyceroneogenesis. Real-time RT-PCR re-
vealed up-regulation of FAS mRNA in visceral adipose tissue in
patients with Cushing’s syndrome compared with the control
patients (240  34.7% of control, P  0.01, Fig. 1D), whereas
values for incidentaloma patients were in between controls and
Cushing’s patients (178.5  29.9% of control) (P  0.12 vs.
controls, P  0.13 vs. Cushing’s). PEPCK mRNA expression
seemed to be higher in patients with Cushing’s syndrome vs.
control subjects, but this did not reach significance (228.79 
50.5% of control, P 0.19).
Discussion
In states of glucocorticoid excess, there is central obesity with
accumulation of the metabolically more disadvantageous intra-
abdominal visceral fat (6). Some of the effects of glucocorticoids
on adipose cell activity and lipid accumulation are more pro-
nounced in visceral than sc fat, suggesting that glucocorticoids
may play a pivotal role in the pathogenesis of the centripetal
obesity characteristic of this condition (15, 18). The higher level
of the local production of active glucocorticoids from inactive
metabolites by visceral adipose tissue 11-hydroxydehydroge-
nase-1 inobesity, togetherwithdata fromthe tissue-specific 11-
hydroxydehydrogenase-1 knockout mice, also supports an im-
portant role of glucocorticoids in the pathogenesis of visceral
adiposity (19). AMPK activation in adipose tissue inhibits lipo-
genesis and lipolysis and stimulates lipid oxidation (20). Thus,
inhibition of AMPK leads to increased lipid stores in association
withenhancedlipolysis, leadingtothereleaseof free fattyacids (20).
Herewe show that excess glucocorticoids are associatedwith
a fall in adipose tissue AMPK activity, and this is supported by
our data in a rodent study as well as in vitro experiments (8).We
hada relatively lownumberof samples, but itmust be considered
that endogenous Cushing’s syndrome is a relatively rare disease
andonly a small proportionof these patients undergo abdominal
surgery, thereby providing the opportunity to obtain visceral
adipose tissue. We used adrenal incidentalomas as a control
group for patients undergoing laparoscopic adrenalectomy but
also included a second group of patients without any adrenal
pathology. Patients with adrenal incidentalomas may show sub-
tle minor defects in corticosteroid secretion and regulation,
sometimes resulting in subclinical Cushing’s syndrome (15–17).
In our cohort five of nine incidentaloma patients did not fully
suppress after 1 mg dexamethasone, and indeed the fall in adi-
pose tissue AMPK activity was intermediate in these patients
compared with those without any adrenal pathology. Our find-
ings of a decreased AMPK activity in the visceral adipose tissue
of patients with Cushing’s syndrome with a consequent increase
in the expression of the lipid synthesizing enzyme FAS could
readily explain the accelerated lipid deposition in visceral adi-
pose tissue upon glucocorticoid excess. Our data also suggest
that the suppression of AMPK activity is proportional to the
glucocorticoid burden. In agreement with the present results, we
previously showed that incubation of human adipocytes with
dexamethasone leads to a fall in AMPK activity, indicative of a
direct effect of glucocorticoids on human adipocyte AMPK (8).
AMPK is a well-known regulator of enzymes in lipid metabo-
lism, and here we show that corticosteroids increase the gene
expression of lipogenic enzyme FAS and a trend to higher
PEPCK,aknowneffectofdecreasedAMPKactivity inother tissues
(7).However, a direct effect of glucocorticoids via the transactivat-
ing effect of thenuclear glucocorticoid receptormayalsoplaya role
(21, 22). Patients with Cushing’s syndrome have increased visceral
but normal or low sc fat, and this corresponds to the data in our
animalmodel of Cushing’s syndrome inwhich glucocorticoids sig-
nificantly decreased AMPK activity in visceral adipose tissue with-
out an effect on sc adipose tissue in the same animals (8).
Metformin is a mainstay of therapy in the treatment of type
2 diabetes, and its glucose-lowering effects are mediated by liver
serine/threonine protein kinase 11 (LKB1), an AMPK upstream
kinase (23). Our recent data in human adipocytes show that
metformin reverses the inhibitory effects of corticosteroids on
AMPK, suggesting thatmetformin and glucocorticoids influence
the AMPK signaling pathway in opposite ways and that met-
formin is able to override the effect of glucocorticoids on this
enzyme. This suggests that metformin or novel tissue-specific
AMPK activators could be beneficial in the prevention or treat-
ment of the deleterious metabolic consequences, especially the
accumulation of the disadvantageous visceral adipose tissue, in
patients with endogenous or iatrogenic Cushing’s syndrome. A
recognized link between AMPK and cortisol could also improve
the development of safer forms of corticosteroid therapy for pa-
tients who require the antiinflammatory actions of glucocorticoids
because there is an intense search for a glucocorticoid-like com-
pound selectively affecting inflammatory pathways (24); the link
suggested by our data between glucocorticoids and AMPK may
assist in the selection of the appropriate drug(s) for this purpose.
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